TB Alliance Receives GHTC Partnership Award for Development of Pretomanid
TB Alliance is honored to accept a 2022 Innovating for Impact Award
WASHINGTON, DC (December 7, 2022)—At the sixth annual Innovating for Impact Awards on Tuesday, December 6, the Global Health Technologies Coalition (GHTC) awarded TB Alliance the Partnership Award for its work in developing pretomanid, a drug used as part of a set regimen to treat highly drug-resistant tuberculosis (TB).
“On behalf of TB Alliance and our partners, we are honored to accept this award from GHTC,” said Mel Spigelman, MD, President and CEO of TB Alliance. “A development like this to treat TB would not have been possible without the strong support and commitment of all our partners, including our funders, and, above all, the participants in our clinical trials.”
The award was accepted by Dr. Spigelman at the ceremony in Washington, DC before an audience of policymakers, US government officials, media, and leaders of the global health and medical research communities. The award is annually presented to an innovative research and development (R&D) partnership that has advanced a high-impact, game-changing global health technology. Honorees are chosen by a committee of global health experts.
This award recognizes TB Alliance’s work with its partners to develop pretomanid, a drug that was first approved in 2019 as part of the BPaL regimen, a three-drug, six-month, all-oral treatment regimen for people with highly resistant forms of TB. Many patients used to take more than 14,000 pills over the course of 18 months or longer without a high chance of successfully curing their highly drug-resistant TB. Now, this is no longer the case.
In addition to recognizing TB Alliance, GHTC presented Dr. Anthony Fauci with a Lifetime Service Award, as well as presented Senator Sherrod Brown (D-OH) and Senator Todd Young (R-IN) each with a Congressional Champion Award for their support of policies and funding to advance the R&D of transformative health tools.
TB Alliance is honored to accept the Innovating for Impact 2022 Partnership Award. For more information about the awards, please visit GHTC’s website.
See GHTC’s video about the Partnership Award:
About TB Alliance
TB Alliance is a not-for-profit organization dedicated to finding faster-acting and affordable drug regimens to fight TB. Through innovative science and with partners around the globe, we aim to ensure equitable access to faster, better TB cures that will advance global health and prosperity. TB Alliance operates with support from Australia’s Department of Foreign Affairs and Trade, Bill & Melinda Gates Foundation, Foreign, Commonwealth and Development Office (United Kingdom), Cystic Fibrosis Foundation, Germany’s Federal Ministry of Education and Research through KfW, Global Disease Eradication Fund (Korea), Global Health Innovative Technology Fund, Indonesia Health Fund, Irish Aid, Korea International Cooperation Agency, Medical Research Council (United Kingdom), National Institute of Allergy and Infectious Diseases, Netherlands Ministry of Foreign Affairs, Republic of Korea’s Ministry of Foreign Affairs, United Kingdom Department for International Development, and the United States Agency for International Development. For more information, please visit: www.tballiance.org.
Media Contact:
Thomas Lynch
+1 917 648 0671
You might also be interested in:
